277 related articles for article (PubMed ID: 16996089)
1. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
Yamada S; Maruyama S; Takagi Y; Uchida S; Oki T
Life Sci; 2006 Dec; 80(2):127-32. PubMed ID: 16996089
[TBL] [Abstract][Full Text] [Related]
2. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
[TBL] [Abstract][Full Text] [Related]
3. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
Ito Y; Oyunzul L; Yoshida A; Fujino T; Noguchi Y; Yuyama H; Ohtake A; Suzuki M; Sasamata M; Matsui M; Yamada S
Eur J Pharmacol; 2009 Aug; 615(1-3):201-6. PubMed ID: 19446545
[TBL] [Abstract][Full Text] [Related]
4. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.
Nelson CP; Gupta P; Napier CM; Nahorski SR; Challiss RA
J Pharmacol Exp Ther; 2004 Sep; 310(3):1255-65. PubMed ID: 15140916
[TBL] [Abstract][Full Text] [Related]
5. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
[TBL] [Abstract][Full Text] [Related]
6. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
Oki T; Sato S; Miyata K; Yamada S
Br J Pharmacol; 2005 May; 145(2):219-27. PubMed ID: 15753946
[TBL] [Abstract][Full Text] [Related]
7. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
Maruyama S; Oki T; Otsuka A; Shinbo H; Ozono S; Kageyama S; Mikami Y; Araki I; Takeda M; Masuyama K; Yamada S
J Urol; 2006 Jan; 175(1):365-9. PubMed ID: 16406943
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
McNamara A; Pulido-Rios MT; Sweazey S; Obedencio GP; Thibodeaux H; Renner T; Armstrong SR; Steinfeld T; Hughes AD; Wilson RD; Jasper JR; Mammen M; Hegde SS
Eur J Pharmacol; 2009 Mar; 605(1-3):145-52. PubMed ID: 19168050
[TBL] [Abstract][Full Text] [Related]
10. In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.
Oki T; Kawashima A; Uchida M; Yamada S
Life Sci; 2005 Apr; 76(21):2445-56. PubMed ID: 15763076
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
Kay GG; Wesnes KA
BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
Hirose H; Aoki I; Kimura T; Fujikawa T; Numazawa T; Sasaki K; Sato A; Hasegawa T; Nishikibe M; Mitsuya M; Ohtake N; Mase T; Noguchi K
J Pharmacol Exp Ther; 2001 May; 297(2):790-7. PubMed ID: 11303071
[TBL] [Abstract][Full Text] [Related]
14. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
Oki T; Toma-Okura A; Yamada S
J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
[TBL] [Abstract][Full Text] [Related]
15. M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder.
Braverman AS; Tibb AS; Ruggieri MR
J Pharmacol Exp Ther; 2006 Feb; 316(2):869-74. PubMed ID: 16243961
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
[TBL] [Abstract][Full Text] [Related]
17. Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors.
White CW; Short JL; Haynes JM; Matsui M; Ventura S
J Pharmacol Exp Ther; 2011 Dec; 339(3):870-7. PubMed ID: 21885618
[TBL] [Abstract][Full Text] [Related]
18. The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics.
Yamada S; Ito Y; Taki Y; Seki M; Nanri M; Yamashita F; Morishita K; Komoto I; Yoshida K
Drug Metab Dispos; 2010 Aug; 38(8):1314-21. PubMed ID: 20483954
[TBL] [Abstract][Full Text] [Related]
19. M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder.
Braverman AS; Doumanian LR; Ruggieri MR
J Pharmacol Exp Ther; 2006 Feb; 316(2):875-80. PubMed ID: 16243962
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
Gillberg PG; Sundquist S; Nilvebrant L
Eur J Pharmacol; 1998 May; 349(2-3):285-92. PubMed ID: 9671109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
